authors contributed equally to this work. One sentence summary: Ly7917: an antimicrobial agent with huge potential for reducing Streptococcus suis reservoirs in the swine industry.
INTRODUCTION
Streptococcus suis (S. suis) is a zoonotic pathogen with 33 serotypes that can result in serious infections in pigs and humans. Streptococcus suis serotype 2 (S. suis 2) is an important zoonotic agent infecting humans who work in close contact with pigs or their products (Wang, Sun and Lu 2009; Meng et al. 2011) and it is also the most frequently isolated strain worldwide from diseased piglets (Lun et al. 2007) , and has developed high-level multi-drug resistance to classic antibiotics especially penicillin G in recent years, sparking an interest in alternative antibacterial agents against S. suis 2.
Endolysins (or lysins) are highly evolved bacterial cell wall peptidoglycan (PG) hydrolases produced by bacteriophage (or phage), which originally occurs to release bacteriophages from host bacterial cells (Fischetti 2010) . Additionally, exogenous administration of purified lysins to PGs causes 'lysis from without' (Nelson et al. 2012 ) with a high bactericidal efficiency and no resistance such that lysins have been thought of as ideal antimicrobial agents capable of controlling pathogens, especially those that cause fatal infections, such as Escherichia coli O157, Salmonella enteritis, Staphylococcus aureus and Listeria monocytogenes. Lysins are generally composed of a single (Tang et al. 2013) . Ly7917 was predicted to have an N-terminal cysteine, histidine-dependent amidohydrolases/peptidase (CHAP) catalytic domain and a C-terminal SH3b cell wall binding domain which always act in a cooperative manner to cleave a specific site of PG (Bateman and Rawlings 2003) , but the detailed biofunctional effect of Ly7917 remains unclear. In this report, the initial characterization of Ly7919 is described.
MATERIALS AND METHODS

Bacterial strains and culture conditions
Details on the provenance of strains used in the current investigation can be found in Table 1 . HA9801 is a virulent strain of S. suis 2 that was first isolated and characterized from dead swine in Jiangsu Province in 1998 (Zhao et al. 2009 ) and tested as the indicator bacteria in transmission electron microscopy (TEM) and in vivo assays. All strains were incubated at 37
• C with 200 rpm shaking speed for growth.
Production of Ly7917
Ly7917 was amplified from genomic DNA of S. suis Phi7917 strain by using the primers F-BamHI (5 -CGGGATCCATGACAACAGTAAATG-3 ) and R-XhoI (5 -GCTCGAGTTATTTAAAAGTACCCCAGGC-3 ) designed on the sequence deposited in GenBank (Accession Number: KC348601) (Tang et al. 2013) , The amplified products were digested with BamHI and XhoI and subsequently ligated into the pSJ2 expression plasmid (Zhang et al. 2013 ) modified from pET21a (+) carrying the ampicillin-resistance gene. The recombinant expression plasmid was transformed into E. coli BL21 (DE3) cells for expression of Ly7917. The N-terminal His-tagged Ly7917 was expressed in E. coli BL21 and induced at 27
• C for 4 h by adding IPTG after OD 600 reached to 0.6. Ly7917 was purified by Ni Sepharose 6 Fast Flow resin gravity column (GE healthcare, USA). Ly7917 eluted in elution buffer (containing 20 mM Na 3 PO 4 , 300 mM NaCl and 200 mM imidazole; pH 7.4) and then dialyzed to remove imidazole in binding buffer (containing 20 mM Na 3 PO 4 , 300 mM NaCl; pH 7.4) for function analysis.
Quantitative and qualitative analysis of Ly7917
HA9801 was resuspended with PBS to a final OD 600 of 0.6 for turbidity decreasing assay (Nelson, Loomis and Fischetti 2001) to define the Unit of Enzyme Activity (UEA) of Ly7917. Then, 1 U ml −1 of Ly7917 (pH 7.4) and HA9801 (PBS; OD 600 = 0.6) were incubated at 37
• C for 10 min and resuspended with 2.5% glutaraldehyde prepared for ultrathin section which was stained by phosphato-tungstic acid for TEM (120 kV BIO-TEM, Tecnai G2 Spirit Biotwin, FEI).
Ly7917 specificity
Ly7917 specificity was determined by the turbidity decreasing assay (Nelson, Loomis and Fischetti 2001) . Selected bacterial strains (Table 1) were grown to OD 600 = 1.0, 0.5 U ml −1 of Ly7917 was added for each test and PBS was used as a negative control. The plate was incubated at 37
• C for 15 min, and the turbidity at OD 600 was measured. The percent of turbidity reduction was calculated according to the readings.
Characteristics of Ly7917
The pH and temperature sensitivities of Ly7917 against HA9801 were assessed as described above. Streptococcus suis HA9801 was grown and assessed as previously described. The pH dependence of Ly7917 was first addressed using two buffer sets with different pH ranges, as follows: citrate/phosphate (pH 4.5-8.0) and bis-Tris propane (pH 8.0-9.5) (Gilmer et al. 2013 
Minimum inhibitory concentration analysis
HA9801 was collected and washed as previously described and finally resuspended with THB to OD 600 = 0.2. The minimum inhibitory concentration (MIC) of Ly7919 was determined and compared to penicillin G (10 000 U kg −1 for clinical therapy). Ly7917
(512 U ml −1 ) was serially 2-fold diluted and mixed with 100 μl of the HA9801 bacterial suspension in 96-well plates. The same treatments performed using Ly7917 were repeated using penicillin G (10 000 U ml −1 ). Three wells were used for each dilution and the plates incubated at 37
• C for 24 h. The MIC was defined as the lowest concentration of antibiotic that resulted in the inhibition of visible growth (Yang et al. 2014) .
Protection from S. suis HA9801 infection
Bacterial growth characteristics in the blood of infected mice For animal studies, 6-week-old female BALB/c mice (obtained from Laboratory Animal Center of Shanghai Jiao Tong University) were intraperitoneally (i.p.) injected with HA9801 at a concentration of 1.4 × 10 7 CFU mouse −1 with a volume of 0.5 ml.
Blood was sampled at multiple time points following infection from three mice by retro-orbital sampling and bacterial concentration in the blood was determined using colony-counting method (Wang et al. 2014) .
Correlation between survival rate and concentration of bacteria in the blood 140 mice were randomly divided into seven groups with 20 mice in each group. Six groups of mice were challenged by HA9801 at a concentration of 1.4 × 10 8 CFU mouse −1 , while one group of mice was used as blank control. At 3 h post infection, blood was sampled from each group to determine the bacterial concentration. And then six challenged groups of mice were treated with three agents respectively: two groups i.p. injected with Ly7917 (512 U ml −1 , 0.5 ml mouse −1 ; 4 × MIC), two groups injected i.p.
with penicillin G (10 000 U ml −1 , 0.5 ml mouse −1 ; 8 × MIC) and the rest two groups of mice were injected i.p. with binding buffer (0.5 ml mouse −1 ) as a negative control. For each treatment, one group was used to determine the survival rate observed at 24 h post infection, and the other group was used to measure the bacterial concentration in blood sampled from the surviving mice at 3 h after treatment. 
Statistical analyses
In all experiments, data points were plotted using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA). Data are presented as mean values ± standard errors of means (SEM). The animal infection was performed using the nonparametric Mann-Whitney U test. A P value of < 0.05 was considered significant.
RESULTS
CHARACTERISTICS of Ly7917
A BLAST search with the Ly7917 amino acid sequence identified a number of Streptococcus phage lysins with a high percentage of sequence identity, including those from the Streptococcus phage phi891591 (92%), Streptococcus phage phiss12 (91%), S. suis 05HAS68 (91%) and S. entericus (74%). Ly7917 was predicted to have an N-terminal CHAP catalytic domain (1-146 aa) and a C-terminal SH3b binding domain (163-227 aa). The molecular weight (29.34 kDa) of His-tagged Ly7917 protein was confirmed by SDS-PAGE assay. The concentration of Ly7917 dialyzed in binding buffer was 4.5 mg ml −1 , and its UEA (Unit of Enzyme Activity) was 512 U ml −1 . In TEM assay, the weakening and rupture of the cell wall resulted in a partial or total loss of cytoplasmic contents and the formation of a cell 'ghost' (Fig. 1) .
In vitro activity of Ly7917
Ly7917 showed effective lytic activity against S. suis, S. equi ssp. zooepidemicus and S. aureus. No lytic activity was observed against B. subtilis, Salmonella or E.coli. Specifically, 0.5 U ml
of Ly7919 showed maximum of lysis activity against strains HA05729-1 and 19-2(A) for more than 40% of decrease in turbidity. The turbidity of S. suis strains 2-4, 5-2 and 05-465 decreased by more than 30%, whereas that of HA9801 decreased by 17%. S. suis serotype 1 isolate str5-2014 was not as sensitive as other serotypes, and even less sensitive than S. aureus to Ly7917 (10%) (Fig. 2) . The isoelectric point of the His-tagged Ly7917 protein was predicted to be 6.79 (EXPASY http://web.expasy.org/compute˙pi/). Ly7917 activity was maintained at a high level at pH 6.0-9.0, and completely lost at pH 4.5 (Fig. S1, Supporting Information) . Catalytic activity of Ly7917 could be enhanced by the addition of Ca 2+ at low concentrations ranging from 10 μM to 1.25 mM, and optimal concentration was determined to be 1 mM (Fig. S2A obviously influence Ly7917 activity (data not shown). EDTA > 0.01 mM showed an inhibitory effect on the Ly7917-induced lysis of HA9801 (Fig. S2B, Supporting Information) . Decrease in turbidity greater than 10% indicated an effective lytic activity. The MIC of Ly7919 was determined to be 0.57 mg ml −1
(64 U ml −1 ) compared to penicillin G 0.4 mg ml −1
(625 U ml −1 ). Multiple strains of S. suis (serotypes 1, 2, 7 and 9), S. equi ssp. zooepidemicus strain ATCC35246, S. aureus strain ATCC25923 and B. subtills strain BS-09 were tested for susceptibility to Ly7917 (0.5 U ml −1 ). BS-09 barely interacted with Ly7917 same as Gram-negative controls E. coli strain MC1061 and Salmonella strain SA925. Streptococcus suis type 1 was less sensitive to Ly7917 than any other strains of S. suis even than S. aureus.
In vivo activity of Ly7917
We investigated whether Ly7919 could protect against S. suis HA9801 infection in vivo. Results showed that HA9801 in mice blood could reach the highest detection level at 2 h after infection and remained at this level for at least 6 h (Fig. S3 , Supporting Information), so the therapy time was determined at 3 h post infection. The concentration of bacteria in blood samples immediately before treatment ranged from 1 × 10 8 to 11 × 10 8 CFU ml −1 . At survival rate, by contrast a 50% (10/20) survival rate with 1-5 × 10 7 CFU ml −1 was observed in the penicillin-G-treated group (Fig. 3) . These results indicated that the survival rate was inversely proportional to the bacterial concentration in blood, and Ly7917 could significantly reduce the bacterial load in the blood of mice (P < 0.05), and it also be more efficient than penicillin G to control HA9801 infection.
DISCUSSION
The novel lysin Ly7917 (1U) quickly lysed HA9801 within 10 min as observed in TEM assay and showed notable stability with tolerance of broad range of pH, and the catalytic activity of Ly7917 was increased by Ca 2+ supplementation with lower concentration than PlyPy (Lood et al. 2014 ).
Ly7917 not only showed efficient lytic activity in vitro, but also excellent performance in an animal challenge study. Thus far, the i.p. challenge of HA9801 on mice might be the most appropriate route of infection for lab research. The time point for lysin injection was critical to the animal survival rate. For example, at the therapy test of PlyG on B. cereus isolate RSVF1 using a mouse model of infection, PlyG (50 U in 0.5 ml) was injected i.p. 15 min after infection, leading to 68.4% survival rate (Schuch, Nelson and Fischetti 2002) . Experiments with 40 μg of either Cpl-1 or Pal administered i.p. shortly (10 min) after the challenge with S. pneumoniae 541 pronounced therapeutic effect with all mice were fully recovered (Jado et al. 2003) . Short interval time between infection and therapy overestimates the protective effect outcome. Herein, therapy induction time for lysin was delayed to 3 h post infection which makes our results more convincing when infection was well underway, as high HA9801 levels were detected 2.5 h post infection. Administration of 180 U of ClyH at 3 h after challenge with 4 × 10 9 CFU AMO25/mouse protected 66.7% of mice and this protective efficacy was improved to 100% when the dose of ClyH was increased to 360 U (Yang et al. 2014 ).
Compared to ClyH, administration of 256 U Ly7917 leading to 90% survival rate seems to be equivalent with ClyH efficiency. PlyPy (0.5 mg) administered 3 h post infection of S. pyogenes MGAS5005 on FVB/NJ mice led to 95% survival (Lood et al. 2014 ) that seems more effective despite of differences of mice and bacteria. Although the turbidity decrease of HA9801 lysed by Ly7917 was not as efficient as exhibited by other less virulent S. suis strains, excellent performance of Ly7917 against HA9801 in vivo also indicated that Ly7917 would kill other S. suis tested in vitro even more efficiently if mice were infected with those less virulent strains.
Conclusively, Ly7917 showed excellent antimicrobial activity against virulent strain HA9801 of S. suis 2 in vivo and other S. suis strains in vitro. Ly7917 may be an ideal alternative to traditional antibiotics for developing a novel antimicrobial therapy against zoonosis caused by S. suis 2 in swine and human.
